← Back to Search

Radiation Therapy

FLASH Radiotherapy for Bone Metastases (FAST-02 Trial)

N/A
Recruiting
Led By John Breneman, MD
Research Sponsored by Varian, a Siemens Healthineers Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed from start of treatment until 6 months post treatment.
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new, very high-dose radiation treatment for people with bone cancer that has spread to their chest. They want to see if it causes side effects and if it relieves pain.

Who is the study for?
Adults over 18 with 1-3 painful bone metastases in the thorax, expected to live more than 6 months, and can follow the study plan. Excluded are those with metal implants in the treatment area, prior radiation or therapy that affects tissue response to radiation within specific timeframes before/after treatment, pregnant or nursing women, and certain medical conditions.
What is being tested?
The trial is testing FLASH Radiotherapy for pain relief and safety in patients with painful bone metastases in the chest area. This new type of radiotherapy is given at much faster rates than conventional treatments.
What are the potential side effects?
Potential side effects may include typical reactions associated with radiotherapy such as skin irritation at the treatment site, fatigue, nausea, and inflammation of surrounding tissues. Specific side effects related to FLASH Radiotherapy's high-speed delivery will be closely monitored.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed from start of treatment until 6 months post treatment.
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed from start of treatment until 6 months post treatment. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assessment of pain relief using patient reported pain questionnaire for overall pain score
Pain
Assessment of radiation-related toxicities that are possibly, probably, or definitely related to FLASH radiotherapy.
+1 more
Secondary study objectives
Workflow feasibility - delays in study treatment
Workflow feasibility - time on table

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: FLASH radiotherapy for painful bone metastasis(-es)Experimental Treatment1 Intervention
FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FLASH Radiotherapy
2020
N/A
~10

Find a Location

Who is running the clinical trial?

Varian, a Siemens Healthineers CompanyLead Sponsor
34 Previous Clinical Trials
7,217 Total Patients Enrolled
John Breneman, MDPrincipal InvestigatorMedical Director Cincinnati Children's/UC Health Proton Therapy Center
1 Previous Clinical Trials
10 Total Patients Enrolled

Media Library

FLASH Radiotherapy (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05524064 — N/A
Bone Metastases Research Study Groups: FLASH radiotherapy for painful bone metastasis(-es)
Bone Metastases Clinical Trial 2023: FLASH Radiotherapy Highlights & Side Effects. Trial Name: NCT05524064 — N/A
FLASH Radiotherapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05524064 — N/A
~1 spots leftby Apr 2025